Targeting the Tumor Microenvironment with Immunotherapy for Genitourinary Malignancies

Area of Science:

• Oncology
• Immunology
• Genitourinary Cancers

Background:

• Immunotherapy, including Bacillus Calmette-Guérin, high-dose interleukin-2, and sipuleucel-T, has demonstrated the potential of harnessing the host immune response against genitourinary malignancies.
• Immune checkpoint inhibitors (ICIs) have recently revolutionized treatment for urothelial carcinoma and renal cell carcinoma, offering durable responses in some patients.
• However, a significant proportion of patients do not respond to ICIs, and progression or relapse remains a challenge, particularly with limited efficacy of ICIs as monotherapy in advanced prostate cancer.

Purpose of the Study:

• To highlight the need for novel treatment strategies in genitourinary cancers.
• To emphasize the critical requirement for improved biomarkers to guide patient selection and predict treatment response to immunotherapy.
• To advocate for research into synergistic and rational combination therapies to enhance response rates and survival.

Main Methods:

• Review of existing literature on immunotherapy in genitourinary malignancies.
• Analysis of the successes and limitations of current immunotherapeutic approaches, including immune checkpoint inhibitors.
• Identification of key areas for future research, focusing on combination strategies and biomarker development.

Main Results:

• Immunotherapy has shown significant promise but is not universally effective in genitourinary cancers.
• Many patients exhibit resistance or relapse despite treatment with immune checkpoint inhibitors.
• Current biomarkers are insufficient for optimal patient selection and predicting response.

Conclusions:

• Novel treatment approaches are urgently needed for genitourinary malignancies.
• Optimizing the sequencing, timing, and combination of immuno-oncology agents with other therapies is essential.
• Validation of novel biomarkers is critical to personalize immunotherapy and improve outcomes across diverse genitourinary cancers.